Wellington Management Group
CBAY

Wellington Management Group’s Cymabay Therapeutics CBAY Stock Holding History

Wellington Management Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-202,782
Closed -$4.79M – 1997
2023
Q4 		$4.79M Buy
+202,782
New +$3.61M ﹤0.01% 1321
2023
Q2 		– Sell
-152,487
Closed -$1.33M – 2058
2023
Q1 		$1.33M Buy
+152,487
New +$1.22M ﹤0.01% 1584
2019
Q4 		– Sell
-1,855,827
Closed -$9.5M – 2148
2019
Q3 		$9.5M Sell
1,855,827
-59,288
-3% -$359K ﹤0.01% 1177
2019
Q2 		$13.7M Buy
1,915,115
+101,125
+6% +$1.15M ﹤0.01% 1112
2019
Q1 		$24.1M Buy
+1,813,990
New +$19.3M 0.01% 964

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wellington Management Group's CBAY Position: Q1 2024 in Review

Wellington Management Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 202,782 shares — an estimated $4.79M sold.

Wellington Management Group first reported a position in CBAY in Q1 2019 and held it in 5 quarters. The position peaked at $24.1M in Q1 2019. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Wellington Management Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wellington Management Group sold 202,782 Cymabay Therapeutics shares in Q1 2024, an estimated $4.79M.
  • Wellington Management Group first reported a position in Cymabay Therapeutics in Q1 2019 and held it in 5 quarters.
  • Wellington Management Group's Cymabay Therapeutics position peaked at $24.1M in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Wellington Management Group's 13F filing for Q1 2024, filed 15 May 2024.